OncoSec Medical Inc (ONCSQ)

[jondoeuk]

''I also slightly wondered about the function / addition of a TLR3 in such a combo (the trial I referenced to several months ago used a Flt3L with TLR3 and SBRT).''

Dr. Brody has presented some data. It shows that two have had partial responses (Cheson criteria) including untreated lesions, persisting and/or improving for over 6 months post vaccination. This includes regressions of bulky lesions https://pbs.twimg.com/media/Cl54gGCUkAEIAJa.jpg as well as disease in the peripheral blood and bone marrow. Another two have SD. Concurrent increase in non-malignant B-cells and mild AEs have been noted. He has secured funding for a larger trial in both solid tumours and lymphomas testing that with an anti-PD-1 (pembro).

He has also hinted at using oncolytic viruses over low-dose radiotherapy and TLR agonists. Unpublished data show that the NDV is able to cure around 10% of mice, but with Flt3L it's around 70%.

For solid tumours using agonists for TLRs 7, 8 & 9* should work better than just a TLR3 https://jitc.biomedcentral.com/articles/10.1186/2051-1426-2-12

* $DVAX have two TLR9 agonists (SD-101 & DV281) in trials and are working on a number of TLR7/8s